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ABSTRACT RiVax is a promising recombinant ricin toxin A subunit (RTA) vaccine
antigen that has been shown to be safe and immunogenic in humans and effective
at protecting rhesus macaques against lethal-dose aerosolized toxin exposure. We
previously used a panel of RTA-specific monoclonal antibodies (MAbs) to demon-
strate, by competition enzyme-linked immunosorbent assay (ELISA), that RiVax elicits
similar serum antibody profiles in humans and macaques. However, the MAb bind-
ing sites on RiVax have yet to be defined. In this study, we employed hydrogen
exchange-mass spectrometry (HX-MS) to localize the epitopes on RiVax recognized
by nine toxin-neutralizing MAbs and one nonneutralizing MAb. Based on strong pro-
tection from hydrogen exchange, the nine MAbs grouped into four spatially distinct
epitope clusters (namely, clusters I to IV). Cluster I MAbs protected RiVax’s -helix B
(residues 94 to 107), a protruding immunodominant secondary structure element
known to be a target of potent toxin-neutralizing antibodies. Cluster II consisted of
two subclusters located on the “back side” (relative to the active site pocket) of
RiVax. One subcluster involved -helix A (residues 14 to 24) and -helices F-G (resi-
dues 184 to 207); the other encompassed -strand d (residues 62 to 69) and parts of
-helices D-E (154 to 164) and the intervening loop. Cluster III involved -helices C
and G on the front side of RiVax, while cluster IV formed a sash from the front to
back of RiVax, spanning strands b, c, and d (residues 35 to 59). Having a high-
resolution B cell epitope map of RiVax will enable the development and optimiza-
tion of competitive serum profiling assays to examine vaccine-induced antibody re-
sponses across species.
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Ricin is one of a small group of plant and bacterial toxins that are classified at thedomestic and international levels as potential agents of bioterrorism (1, 2). Ricin is
a product of castor beans (Ricinus communis), which are cultivated globally for their oils
that are used in industrial lubricants, cosmetics, and biofuels. The toxin itself is an
65-kDa glycoprotein that makes up 5% of the dry weight of a castor bean. The toxin
can be purified by relatively simple affinity chromatography (3, 4). On a cellular level,
ricin exerts its cytotoxic effects through ribosome inactivation and triggering of pro-
grammed cell death (5). Ricin’s binding subunit, ricin toxin B subunit (RTB), is a
galactose/N-acetyl galactosamine (Gal/GalNAc)-specific lectin that promotes toxin entry
into mammalian cells, while ricin’s enzymatic subunit, RTA, is an RNA N-glycosidase (EC
3.2.2.22) that, when successfully delivered into the cytoplasm, cleaves the sarcin-ricin
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loop (SRL) of 28S rRNA, thereby stalling ribosome translocation (6, 7). At the tissue level,
particularly in the context of the lung, ricin induces severe inflammation with a marked
influx of neutrophils, alveolar edema, and hemorrhages (8, 9). Nonhuman primates
(rhesus macaques) exposed to ricin by aerosol succumb to the effects of the toxin
within 24 to 52 h (8, 10). At this time, medical intervention following ricin exposure is
strictly supportive (11).
Current efforts to develop a ricin toxin vaccine for military and other at-risk person-
nel are focused on two different recombinant RTA-based subunit antigens, RiVax and
RVEc (12). RTA itself is a globular protein with a total of 10 -strands (namely, strands
a to j) and seven -helices (namely, -helices A to G). The toxin subunit folds into three
distinct domains. Domain 1 (residues 1 to 117) is dominated by a six-stranded -sheet,
domain 2 (residues 118 to 210) is dominated by five -helices, and domain 3 (residues
211 to 267) interfaces with RTB through hydrophobic interactions and a single disulfide
bond (13, 14). RTA’s active site constitutes a shallow pocket formed at the interface of
the three domains (14, 15). Active site residues include Tyr80, Tyr123, Glu177, Arg180,
and Trp211. RiVax is a full-length (267-amino-acid) variant of RTA with two point
mutations, one (Tyr80Ala) that virtually abolishes RTA’s RNA N-glycosidase activity and
one (Val76Met) that disrupts a motif associated with vascular leak syndrome (VLS) (16,
17). The tertiary structure of RiVax is essentially identical to that of RTA, as demon-
strated by X-ray crystallography (18). RVEc, by contrast, is a truncated version of RTA
that lacks domain 3 (residues 199 to 267) and also a small hydrophobic loop in the N
terminus (residues 34 to 43) (19–21).
Because human efficacy trials are not ethical in the case of biothreat agents,
including ricin, the advanced development of vaccines and eventual marketing ap-
proval by the Food and Drug Administration (FDA) in the United States must adhere to
the so-called Animal Rule, which states that a product will be approved only if there are
well-defined correlates of protection in one or more animal models that are predictive
of a response in humans (22). In the case of ricin toxin, neither serum antibody (Ab)
titers nor toxin-neutralizing activities are likely to be sufficiently predictive of protective
immunity across species to serve as stand-alone markers in vaccine evaluation studies
(12, 23–25). However, we recently demonstrated that nonhuman primates and human
volunteers vaccinated with RiVax had similar serum antibody profiles in a competition
enzyme-linked immunosorbent assay (ELISA) performed with a limited panel of
RTA-specific mouse IgG monoclonal antibodies (MAbs), including several with potent
toxin-neutralizing activity (TNA) (10). In that study, the vaccinated nonhuman primates
were protected against lethal-dose ricin challenge administered by aerosol. Immunity
was attributed to the presence of vaccine-induced, ricin-specific IgG antibodies in
serum and/or bronchial fluids.
We have previously argued that it is critical to define the antibody repertoire and B
cell epitopes associated with protective immunity to ricin toxin for vaccine develop-
ment (12). Characterization of different collections of RTA-specific MAbs has indicated
that the antibody response to ricin toxin is dominated by nonneutralizing (and even
some toxin-enhancing) antibodies (26–32). Neutralizing antibodies are relatively rare,
estimated at 10% of the total ricin-specific pool. Complicating matters is the fact that
there is often a disconnect between in vitro toxin-neutralizing activity and the capacity
of a given MAb to neutralize ricin in an animal model (28, 33). In other words, MAbs that
have potent toxin-neutralizing activity in a cell-based assay may or may not passively
protect mice from ricin intoxication. The two primary factors currently associated with
in vivo toxin-neutralizing activity are relative binding avidity and epitope specificity (12,
18, 28, 30, 34, 35). B cell epitope mapping studies of RTA have been conducted using
peptide arrays (pepscan), peptide affinity enrichment by phage display, site-directed
mutagenesis, differential reactivity with Ricinus communis agglutinin 1 (RCA-1), com-
petition ELISAs, and surface plasmon resonance (SPR) analysis (28, 30, 34, 36–38). X-ray
crystallography is also being used to define the structural B cell epitopes on RTA,
although these studies have been restricted (with one exception) to the use of
single-domain camelid antibodies (37, 39–42).
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Extensive characterization and epitope mapping studies of our collection of toxin-
neutralizing and nonneutralizing murine MAbs have suggested that there are at least
four spatially distinct epitope clusters (namely, clusters I to IV) on RTA (Table 1) (30, 34).
Cluster I is defined by three MAbs, namely, PB10, R70 (UNIVAX 70), and WECB2. All three
MAbs have potent toxin-neutralizing activity and have been shown to passively protect
mice against lethal-dose ricin challenge. Cluster II is defined by four MAbs (SyH7, PA1,
TB12, and PH12), while clusters III and IV are defined by MAbs IB2 and GD12, respec-
tively. The six MAbs from clusters II to IV neutralize ricin toxin in vitro and in vivo with
roughly similar potencies (30, 34, 43). We tentatively assigned the locations of clusters
I and II on the surface of RiVax based on strong reactivity of PB10 and R70 with peptides
spanning residues 97 to 108 (corresponding to RTA’s -helix B) and on weak reactivity
of SyH7 with peptides spanning residues 187 to 198 (corresponding to RTA’s -helix F)
(30, 34, 44). The other MAbs (except for GD12, as noted below) were assigned to a
cluster based on competitive binding assays, because they were not reactive with RTA
peptide arrays.
The goal of the current study was to define at high resolution the epitopes on RiVax
recognized by the nine toxin-neutralizing MAbs, as well as one nonneutralizing MAb (JD4),
currently grouped within epitope clusters I to IV. Hydrogen exchange-mass spectrometry
(HX-MS) was the method of choice based on recent success in a wide variety of pathogens,
including HIV, the malaria parasite, Neisseria meningitidis, and Staphylococcus aureus (45–
50). In a recent study, we successfully adapted HX-MS for the purpose of identifying
epitopes recognized by a family of RTA-specific single-domain alpaca-derived antibodies
(VHHs) (51). We also used HX-MS to assist in epitope refinement of a subset of the 68 VHHs
described in a companion paper (71). We now report the contact points on RiVax recog-
nized by 10 MAbs in epitope clusters I to IV. The results afforded by HX-MS validate, for the
most part, the previous competition ELISAs and epitope mapping studies. More impor-
tantly, they provide a rationale to begin the development of much-needed preclinical
assays to gauge the integrity of toxin-neutralizing epitopes on the vaccine antigen and in
the development of sensitive competitive binding assays for serum profiling to examine
vaccine-induced antibody responses across species.
RESULTS
Four distinct clusters of neutralizing B cell epitopes on RiVax. We have previ-
ously assigned a collection of nine RTA-specific, toxin-neutralizing MAbs into four
competition clusters (clusters I to IV), based on the results of pepscan analysis, reactivity
with RTA point and deletion mutants, and competition ELISAs (Table 1; see also Table
S1 and Fig. S1 in the supplemental material) (30, 34, 43, 44). PB10, R70, and WECB2 were
assigned to cluster I, while SyH7, PA1, TB12, and PH12 constitute cluster II (Table 1; see
also Fig. S1). Cluster III is defined by IB2, while cluster IV has been defined historically
by GD12 (34). However, the competition matrix in Fig. S1 indicates that GD12 partially
competes with PB10 and R70, suggesting that clusters I and IV may be adjacent to each
TABLE 1 RTA-specific mouse MAbs used in this study
MAb Subclass Cluster Reference
PB10 IgG2b I 30
R70 IgG1 38
WECB2 IgG1 34




IB2 IgG1 III 34
GD12 IgG1 IV 43
(JD4)a IgG1 34
aMAb JD4 is indicated in parentheses to denote that it is a nonneutralizing antibody.
B Cell Epitopes on RiVax Clinical and Vaccine Immunology
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other. A tenth nonneutralizing MAb, JD4, was grouped within cluster IV based on its
competition with GD12 (see Table S1 and Fig. S1).
RiVax’s regions of intrinsic flexibility and rigidity. HX-MS is increasingly being
used for the purpose of B cell epitope identification (47, 49, 50, 52, 53). The general
principles of HX-MS and how the technique relates to other epitope mapping strategies
have been covered in several recent reviews (45, 54). In a particularly informative study,
Malito and colleagues subjected a single MAb directed against factor H binding protein
from Neisseria meningitidis to epitope mapping by peptide array, HX-MS, and X-ray
crystallography (50). Although HX-MS lacks the atomic resolution of X-ray crystallog-
raphy, the two techniques were in congruence in terms of defining the primary MAb
contact regions on the target antigen.
With the goal of using HX-MS for epitope mapping purposes in the case of ricin, we
first established the baseline backbone flexibility of RiVax to enable us to properly
evaluate changes in protection upon antibody binding. RiVax was subjected to HX and
quenched after 13 s of labeling before being subjected to pepsin digestion and MS
analysis, as described in Materials and Methods. The distribution of backbone flexibility
values was best described by categorization into three groups, according to k-means
clustering: rigid, intermediate, and flexible. There were clearly defined regions of
flexibility and rigidity across the different RiVax secondary structural elements (Fig. 1).
FIG 1 Relative levels of backbone flexibility of RiVax, as determined by HX-MS. RiVax was subjected to HX-MS
analysis, as described in Materials and Methods. The extent of hydrogen exchange (HX) at 13 s for each RiVax
peptide is shown in panel A. The peptides are color coded according to the results of k-means categorization as
follows: rigid, blue; intermediate, gray; flexible, yellow. The peptide number indicates a sequential arrangement
from the N terminus to the C terminus. The peptide assignments are provided in Table S1 in the supplemental
material. (B) The flexibility categories mapped onto the structure of RiVax.
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Here, and in subsequent figures, the peptides are numbered sequentially from the
most N-terminal peptide to the most C-terminal peptide (see Table S2 in the supple-
mental material). For a point of reference, flexible regions include the N and C termini,
the proximal end of -helix A, the proximal end of -helix B, -strand a, -strand h and
surrounding loops, the loop connecting -helices D, E, and G, and the -sheet formed
by -strands i and j (Fig. 1; yellow). Rigid regions include portions of -helix A, the small
-sheet formed by strands b and c, -strands d, e, f, and g and connecting loops, the
C-terminal half of -helix B, -helices C and D and the connecting loop, -helices E and
F and the connecting loop, the N-terminal portion of -helix G, and the 3/10 helix in the
C-terminal region (Fig. 1; blue). The remaining secondary structural elements were
classified as intermediate.
HX-MS analysis of RiVax bound to cluster I MAbs (PB10, R70, and WECB2). To
apply HX-MS for epitope mapping of RiVax, we initiated studies with PB10, the murine
MAb that defines cluster I (30). PB10’s epitope has been assigned with confidence to a
linear stretch of residues within RiVax’s -helix B (residues 98 to 106), as demonstrated
by pepscan analysis and affinity enrichment studies performed with a phage-displayed
peptide library (30, 44). These studies are supported by additional epitope mapping
experiments using a collection of RTA site-directed point and deletion mutants (34).
HX-MS analysis of RiVax was performed at five exchange times between 13 s and 24
h, using protocols essentially in line with well-established HX-MS methodologies (Fig.
2) (55–58). For the labeling studies, PB10 was at 2-fold molar excess relative to RiVax to
favor complex formation. As expected, there were distinct differences in the rates of HX
by peptides in the presence of PB10. As shown in Fig. 2A and B, the rate of HX by
peptide 1 (residues 0 to 11) was unaffected by PB10, while HX of peptide 38 (residues
93 to 107) was considerably slower in the presence of PB10. A reduction in HX across
a peptide is interpreted as protection due to protein-protein contacts and, therefore,
diagnostic of epitopic regions (45). The magnitude of this protection was quantified




where Δm denotes the measured mass increase for each peptide and the infinity
subscript indicates HX measured in a deuteration control. The ΔHX data from each of
the five HX times are shown in Fig. 2C to G. These values were then averaged (ΔHX) as
shown in Fig. 3, using a methodology described elsewhere (R. Toth IV, S. K. An-
galakurthi, M. J. Rudolph, D. Volkin, C. R. Middaugh, N. J. Mantis, and D. Weis, unpub-
lished data), and were applied successfully to VHH-RTA interactions, where we com-
pared the HX-MS output to a known X-ray crystal structure (51). The magnitudes of
altered HX were classified by k-means clustering into four categories and were color
coded accordingly as follows: strong protection, deep blue; intermediate protection,
light blue; no protection, gray; deprotection, yellow. Averaged or summed HX differ-
ences are used widely in the HX-MS field, as noted in the citation provided above. It has
been shown, for example, that the area between HX curves is proportional to the
change in protection from HX (56, 58). Specifically, for HX measurements that are
equally spaced on a log scale, the area between the HX curves is proportional to the
average HX difference that we have used, i.e., ΔHX. Therefore, this form of represen-
tation is used throughout the remainder of this work.
To visually define the locations of altered HX, the averaged differences were
mapped onto the surface of RiVax (Fig. 4A). In the presence of PB10, HX-MS revealed
strong protection (i.e., slower hydrogen exchange) across peptides 34 to 36 and
peptides 38 to 41, corresponding to RiVax residues 94 to 107 (Table 2 and Fig. 2), which
is consistent with PB10’s proposed core epitope based on peptide mapping studies (30,
44). Peptide 114, which encompasses RiVax residues 243 to 244 and includes the loop
following strand j, was also strongly protected, although its distance from PB10’s core
binding site would suggest that its protection is due to allostery rather than direct
contact (Fig. 4A). PB10 induced intermediate degrees of protection at two different
B Cell Epitopes on RiVax Clinical and Vaccine Immunology
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FIG 2 HX-MS analysis of RiVax in the presence of PB10. RiVax was subjected to HX-MS analysis in the absence or
presence of MAb PB10. (A and B) HX kinetics of two representative RiVax peptides. Panel A shows peptide 1 (residues
0 to 11), where the rate of HX was unaffected by PB10. Panel B shows peptide 38 (residues 93 to 107), where the rate
(Continued on next page)
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sites, i.e., residues 209 to 218 (represented by peptides 95 and 98) and residues 244 to
256 (peptides 117 and 119 to 125) near RiVax’s C terminus. Discerning whether the
observed intermediate regions of protection constitute actual antibody binding sites, as
opposed to distal effects, is difficult and we have chosen in this study to limit our
conclusions to areas of strong protection. PB10 illustrates the challenges associated
with interpreting intermediate protection. Residues 244 to 256 are situated on the face
opposite -helix B and are therefore not readily accessible to PB10 when bound to its
core epitope, as defined by strong protection across two or more adjacent peptides.
Residues 209 to 218 (encompassing -helix G) could conceivably constitute a contact
point based on its spatial location, but competition assays suggest otherwise (as noted
below). Finally, we noted that RiVax peptide 48 (residues 125 to 129; -helix C) was
deprotected (i.e., showed faster hydrogen exchange) in the presence of PB10 (Fig. 3A
FIG 2 Legend (Continued)
of HX was substantially slowed by PB10. The filled squares denote RiVax alone. The open symbols denote RiVax bound
to PB10. (C to G) The uptake at each HX time for RiVax labeled alone was subtracted from the uptake in the presence
of PB10, resulting in mass differences that are plotted at (C) 13 s, (D) 100 s, (E) 1,000 s, (F) 10,000 s, and (G) 86,000 s
(24 h) of labeling. Error bars represent the standard deviations of triplicate measurements propagated through the
mass differences.
FIG 3 Relative levels of protection of RiVax peptides by PB10, R70, and WECB2, as defined by HX-MS. RiVax was subjected to HX-MS
analysis in the presence of (A) PB10, (B) R70, and (C) WECB2. The ΔHX values for each RiVax peptide are shown and colored according
to their k-means categorization as follows: strong protection, deep blue; intermediate protection, light blue; insignificant protection,
gray; deprotection, yellow.
B Cell Epitopes on RiVax Clinical and Vaccine Immunology
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and 4A). Deprotection near -helix C indicates that the backbone amine residues are
more susceptible to hydrogen exchange in the presence of PB10, most likely due to
allosteric effects as a consequence of antibody contact with -helix B. It is interesting
that peptide 14 (residues 125 to 129) was classified as being rigid (Fig. 1) and therefore
not particularly prone to HX at baseline. Thus, even small allosteric changes in back-
bone flexibility would result in notable deprotection.
We next investigated the two other cluster I MAbs, R70 and WECB2. On the basis of
peptide reactivity, binding to RTA deletion and point mutants, and competition with
PB10, it is proposed that R70 recognizes a linear epitope encompassing portions of
-helix B (residues 97 to 108), whereas WECB2 binds a conformational epitope includ-
ing -helix B (34, 38, 44). The results of HX-MS epitope mapping of R70 and WECB2 are
summarized in Table 2 and Fig. 3 and 4. We observed strong protection for R70 across
the entirety of -helix B (residues 94 to 107; peptides 34 to 41). In this respect, R70 is
identical to PB10. In the case of R70, however, there were additional sites of interme-
diate protection in peptides bracketing -helix B which could have been due to
FIG 4 Visual presentation of the core epitopes of PB10, R70, and WECB2 on RiVax. HX protection
categories, as defined in the Fig. 3 legend, are shown mapped onto the structure of RiVax for (A) PB10,
(B) R70, and (C) WECB2. The image is color coded according to the Fig. 3 legend. The most relevant
secondary structures, -strand h and -helix B, are labeled.
Toth et al. Clinical and Vaccine Immunology
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additional antibody contacts (Fig. 3). However, unlike PB10, R70 did not alter exchange
rates at distal sites beyond -helix B.
WECB2 strongly protected two distinct RiVax secondary structural elements: -helix
B (residues 94 to 107; peptides 32 to 36 and 38) and -strand h (residues 110 to 122;
peptides 43 to 44). WECB2’s epitope, when mapped onto the solvent-accessible surface
of RiVax, is considerably larger than PB10’s epitope (Fig. 4). This difference may explain
why WECB2 has slightly more potent toxin neutralizing activity than PB10 (34). WECB2
induced intermediate protection around -helix C (residues 125 to 135; peptides 48 to
52), the C-terminal end of -helix D, and the N terminus of -helix E and the preceding
loop (residues 154 to 167; peptides 65 and 67) (Fig. 4). It is interesting that within
-helix C, residues Q129 and L130 have side chains oriented toward WECB2’s primary
epitope (see Fig. S2 in the supplemental material), raising the possibility that the
intermediate protection detected across this region is due to direct contact with WECB2
rather than to an allosteric effect. WECB2, like PB10, induced protection near RiVax’s C
terminus (residues 249 to 255; peptides 122, 124, and 125). In summary, the HX-MS
results demonstrate that all three cluster I MAbs, PB10, R70, and WECB2, recognize
epitopes focused on -helix B, a known immunodominant element of ricin toxin (59).
Epitope mapping of the cluster II toxin-neutralizing MAbs (SyH7, PA1, PH12,
and TB12). Cluster II is defined by four different MAbs: SyH7, PA1, PH12, and TB12
(Table 1). SyH7’s epitope was tentatively localized by pepscan analysis to RiVax residues
TABLE 2 Summary of HDX analysis of RiVax bound by cluster I to IV MAbs
MAb Cluster
Strongly protected elements of RiVaxa
Peptide no. Residue no.
Secondary
structure(s)
PB10 I 34–36, 38–41 94–107 -Helix B
114 243–244
R70 34–41 94–107 -Helix B
WECB2 32–36 94–107 -Helix B
38 95–107 -Helix B
43–44 110–122 -Strand h
SyH7 II 2–4 14–24 -Helix A
80–86 184–207 -Helix F, -helix G
PA1 80–85 184–204 -Helix F, -helix G
TB12 16–18 60–69 -Strand d
66 155–164 -Helices D-E
PH12 17–19 62–69 -Strand d
65–66 154–164 -Helices D-E
IB2 III 46–50 121–135 -Helix C
52 129–135 -Helix C
88, 89, 91 207–217 -Helix G
123–124 251–254
GD12 IV 8, 9, 11–13 35–59 -Strands b, c, and d
JD4 123–125 251–255
aPeptides and corresponding residues on RiVax are indicated in Table S1.
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187 to 198, which correspond to -helix F and the F-G loop (30, 34). The other three
MAbs (PA1, PH12, and TB12) compete with SyH7 for binding to ricin but recognize
nonlinear (discontinuous) epitopes and, therefore, were negative by pepscan analysis
(34).
HX-MS analysis revealed that SyH7 strongly protected two regions of RiVax: residues
14 to 24 (peptides 2 to 4), corresponding to -helix A and a preceding -turn, and
residues 184 to 207 (peptides 80 to 86), corresponding to -helix F and the N-terminal
half of -helix G (Table 2 and Fig. 5 and 6). The regions of strong protection form a large
patch that is situated on the “back side” of the molecule, relative to the active site. This
region of RTA is proposed to initiate contact with ribosomes (15, 60). SyH7 binding also
resulted in deprotection of residues 62 to 69, 129 to 135, and 148 to 151 (peptides 17
to 18, 51 to 53, and 60 to 61) (Fig. 5 and 6), which are peripheral to SyH7’s core epitope.
Deprotection of these peptides could be the result of relaxation of the structure
through stress created by the primary antibody binding site (61).
The pattern of altered HX induced by PA1 was similar to that shown by SyH7, in that
PA1 strongly protected -helix F and the N-terminal end of -helix G (Table 2 and
FIG 5 Relative levels of protection of RiVax peptides by SyH7, PA1, TB12, and PH12, as defined by HX-MS. The ΔHX
values for each RiVax peptide are shown for MAbs (A) SyH7, (B) PA1, (C) TB12, and (D) PH12. The ΔHX values are
color coded according to the Fig. 3 legend.
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FIG 6 Visual presentation of the core epitopes of SyH7, PA1, TB12, and PH12 on RiVax. HX protection
categories, as defined in the Fig. 5 legend, are shown mapped onto the structure of RiVax for (A) SyH7,
(B) PA1, (C) TB12, and (D) PH12. The image is color coded according to the Fig. 5 legend. The locations
of -strands a, d, and e as well as -helices A, E, F, and G are indicated.
B Cell Epitopes on RiVax Clinical and Vaccine Immunology
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Fig. 5 and 6). PA1 differed from SyH7 in that it did not strongly protect -helix A. Thus,
PA1’s core epitope appears to be nested within SyH7’s epitope. If regions of interme-
diate protection are taken into account, however, then PA1’s footprint potentially
encompasses the N terminus of -helix A (residues 14 to 24; peptides 2 to 4), -helix
D-E and the intervening loop (residues 136 to 151 and 154 to 164; peptides 55 to 57,
59, and 64 to 66), and RiVax’s C terminus (residues 257 to 267; peptides 126 to 128) (Fig.
6). Without further validation studies, it would be premature to conclude that the areas
of intermediate protection constitute actual antibody binding sites.
The epitopes recognized by TB12 and PH12 were also mapped with HX-MS. As
shown in Fig. 5 and 6, TB12 and PH12 have very similar epitopes. Both MAbs strongly
protected RiVax peptides spanning a region between -strands d and e (residues 60 to
69; peptides 16 to 18), as well as the loop and -turn preceding -helix E (residues 155
to 164; peptide 66) (Table 2). The two epitopes are not identical, however, as the
magnitudes of intermediate protection and zones of deprotection were different (Fig.
5 and 6). We conclude that cluster II consists of two distinct epitope subclusters: one
defined by SyH7 and PA1 and the other by TB12 and PH12. These epitope mapping
results partially explain the differential pairwise competition results observed by ELISA
(see Fig. S1 in the supplemental material).
Epitope mapping of cluster III (IB2) and cluster IV (GD12 and JD4) MAbs. Cluster
III is represented by a single MAb, IB2, whose epitope has been postulated to encom-
pass the C terminus of RiVax (34). HX-MS analysis indicated that IB2 strongly protected
RiVax’s -helix C and the following loop (peptides 46 to 50 and 52; residues 121 to 135),
as well as -helix G (residues 207 to 217; peptides 88, 89, and 91) (Fig. 7). These two
strongly protected elements form a patch below and to the left of the RTA’s active site
(Fig. 7B). A region near the C terminus of RTA (residues 251 to 254; peptides 123
and124) was also strongly protected by IB2.
Cluster IV is represented by two MAbs, GD12 and JD4. Based on admittedly weak
reactivity with an 18-mer RTA peptide array, GD12 was proposed to recognize a linear
FIG 7 Localization of the core epitope of IB2 on RiVax. (A) The ΔHX values for each RiVax peptide shown
for IB2 are indicated and are color coded according to the Fig. 3 legend. (B) The HX protection categories,
as defined for panel A, are shown mapped onto the structure of RiVax. The locations of -helices C and G
are indicated.
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epitope encompassing residues 163 to 174 (43). However, this assignment was con-
tradicted by the HX-MS results. Specifically, GD12 strongly protected residues 35 to 59
(peptides 8, 9, and 11 to 13), which include -strands b and c and the two intercon-
necting -turns (Fig. 8 and 9). GD12’s epitope forms a “sash” from the C terminus of
-helix B to the N terminus side of -strand d located along the back side of RTA and
down to the interface with RTB. The fact that GD12’s core epitope, as determined by
HX-MS, is proximal to (and possibly contacts) -helix B likely explains why the binding
of GD12 to ricin is competitively inhibited by R70 and PB10 (see Fig. S1 in the
supplemental material). We postulate that the reported low-affinity reactivity of GD12
with peptides spanning residues 163 to 174 may constitute a mimitope or even
nonspecific binding, since most of those residues are not surface accessible on RiVax or
RTA.
JD4 has relatively weak affinity for ricin toxin, possibly accounting for its lack of in
vitro toxin-neutralizing activity (Table 1). HX-MS analysis revealed that JD4 did not
strongly protect any region of RTA, except for three peptides (namely, peptides 123 to
125) corresponding to residues 249 to 255 near RTA’s C terminus, which is normally a
region of RTA occluded by RTB (Fig. 8 and 9). JD4 did, however, induce intermediate
protection along nearly the entire length of RTA’s N terminus (residues 1 to 59; Fig. 8).
While the observed region of intermediate protection is consistent with the competi-
tion binding assays performed with GD12, it represents both an unusually large surface
area and, most certainly, an overestimation of actual antibody contact points.
DISCUSSION
In this study, we used HX-MS to localize the epitopes on RiVax recognized by nine
different previously characterized ricin toxin-neutralizing MAbs and one nonneutraliz-
ing MAb. As predicted from cross-competition binding studies, pepscan analysis, and
RTA point and deletion mutant studies (30, 34, 43, 44), the nine toxin-neutralizing MAbs
grouped into four spatially distinct epitope clusters, which cover approximately half the
solvent-exposed surface area of the antigen (Fig. 10). By all accounts, clusters I to IV
represent the most immunodominant elements on the surface of RiVax. Cluster I
epitopes were centered on RiVax’s -helix B, with the epitopes recognized by PB10 and
R70 being nearly identical, while WECB2, which makes additional contact with -strand
FIG 8 Relative levels of protection of RiVax peptides by GD12 and JD4, as defined by HX-MS. The ΔHX values for
each RiVax peptide are shown for MAbs (A) GD12 and (B) JD4. The ΔHX values are color coded according to the
Fig. 3 legend.
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h (residues 110 to 122), had a markedly larger footprint on RiVax. This may explain why
WECB2’s in vitro toxin-neutralizing activity was slightly more potent than that seen with
PB10 and R70 (34). The cluster II epitopes were conveniently distributed into two
subclusters: SyH7 and PA1 contact -helix F and the proximal half of -helix G, while
PH12 and TB12 contact -helices D and E (Fig. 10). IB2, the sole representative of cluster
III in this study, recognizes an epitope encompassing -helices C and G and forms a
diagonal patch on RiVax that borders clusters I and II (Fig. 10). Finally, GD12, a member
of cluster IV, protects -strands b and c and N-terminal elements of d around residue
50 (Fig. 10).
The results presented here have implications for the preclinical evaluation of RiVax.
It was previously reported that sera from RiVax-vaccinated rhesus macaques, as well as
sera from humans, contain antibodies that compete with PB10, R70, WECB2, SyH7, and
PA1 (10). We have now localized the specific epitopes on RiVax recognized by all five
of those particular MAbs. As noted in a recent review (12), there is a particular need for
a surrogate measure of ricin toxin vaccine potency, because neither ricin-specific serum
IgG endpoint titers nor toxin-neutralizing antibody levels are sufficiently robust on their
own to serve as correlates of protection. Indeed, we are currently exploring whether
combinations of these MAbs may serve as tools to interrogate epitope-specific anti-
body responses in the serum of rodents and nonhuman primates vaccinated with RiVax
and whether there is a relationship between epitope-specific responses and survival
following ricin challenge (G. Van Slyke, D. Ehrbar, J. Yates, J. Westfall, and N. Mantis,
unpublished data).
There are several proposed mechanisms by which RTA-specific antibodies might
neutralize ricin toxin in vitro. Legler and colleagues recently demonstrated, using VHHs,
FIG 9 Visual presentation of the core epitopes of GD12 and JD4 on RiVax. Protection categories for (A)
GD12 and (B) JD4, as defined in the Fig. 3 legend, are shown mapped onto RiVax. The locations of
-strands b and c are indicated.
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a correlation between an antibody’s impact on RTA unfolding dynamics and in vitro
toxin-neutralizing activity, possibly due to events associated with ricin endocytosis or
retrograde transport (39). Other reports have shown that anti-RTA MAbs reduced
intracellular transport of ricin from the plasma membrane to the endoplasmic reticulum
(ER) and even prevented protein-disulfide isomerase (PDI)-mediated dissociation of RTA
from RTB in a cell-free assay (62–64). Whether these in vitro activities are relevant in vivo
FIG 10 Summary of HX-MS epitopes on RiVax for clusters I to IV. (A) Strongly protected regions for each MAb are shown in a linear representation
of the primary sequence of RiVax, aligned with a secondary structure cartoon. Coils denote helices, arrows indicate  secondary structure, and
the bulges denote bends. The colored rectangles denote epitopes and are labeled with the corresponding MAb designation. The colors of the
rectangles correspond to epitope clusters as denoted in panel B. (B) The strongly protected regions for each cluster are summed over all MAbs
belonging to that cluster and shown mapped to the crystal structure of the ricin holotoxin (PDB ID: 2AAI) (14), with each cluster colored as
indicated. Where overlaps occurred, they were resolved as follows: cluster III overwrites cluster IV; cluster II overwrites clusters III to IV; and cluster
I overwrites clusters II to IV.
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remains to be determined. The nine toxin-neutralizing MAbs characterized in this report
afford passive immunity to ricin challenge in mice (30, 34), and some MAbs have even
been shown to have therapeutic potential when administered several hours after toxin
exposure (65, 66). A humanized version of PB10 is being evaluated in nonhuman
primates as a possible therapeutic (C. Roy and L. Zeitlin, personal communication).
Understanding the mechanisms by which RTA-specific antibodies protect the lung
mucosa from aerosolized ricin challenge will be of particular importance, especially
considering that the toxin likely engages with both alveolar macrophages and lung
epithelial cells following aerosol exposure. Ricin uptake into macrophages is proposed
to occur via the mannose receptor or other C-type lectins, independently of RTB-
mediated retrograde transport (67, 68). Possible roles for epitope specificity in serum
and mucosal ricin neutralization are under active investigation.
While this report has primarily focused on localizing neutralizing epitopes on RiVax,
it should not be overlooked that a second ricin toxin subunit vaccine, RVEc, was recently
evaluated in humans (23). As noted above in the introduction, RVEc is a truncated
version of RTA that lacks domain 3 (residues 199 to 267), as well as a small hydrophobic
loop in the N terminus (residues 34 to 43) (19–21). The results that have been obtained
by HX-MS epitope mapping studies now explain the observation that IB2, SyH7, PA1,
and GD12 fail to recognize RVEc, in part or in full (34). IB2’s epitope is effectively
removed as a result of RVEc’s C-terminal deletion (Fig. 10), while SyH7 and PA1 have
greatly reduced reactivity with RVEc, which can be explained by the fact that their
epitopes include residues 184 to 207, while RVEc terminates at residue 199. GD12 is
similarly unable to recognize RVEc but for a different reason. The deletion of the small
loop, corresponding to residues 34 to 43, removes approximately half of GD12’s
epitope (residues 35 to 59). The loss of epitopes corresponding to clusters III and IV, as
well as to part of cluster II, explains why RVEc immunization results in a slight bias for
antibodies against cluster I compared to RiVax (69). Nonetheless, in spite of lacking
what are seemingly important neutralizing B cell epitopes, RVEc has proven as effective
as RiVax at eliciting immunity to ricin in mice across a range of doses and with different
adjuvants (69, 70).
The nine toxin-neutralizing MAbs that were subjected to epitope mapping in this
study (Table 1) were used in a study, reported in a companion paper, of competition
ELISAs for the purpose of localizing the binding sites of a large collection of VHHs (71).
As part of that study, we reported the full-length DNA sequences, binding affinities, and
neutralizing activities of 31 VHHs against RTA, 33 against RTB, and 4 against ricin
holotoxin. Remarkably, the epitopes of the RTA-specific VHHs localized within one or
more of the four clusters defined in this study (Fig. 10). The fact that no RTA-specific
VHHs that fell outside these four clusters were identified is a testament to the degree
of coverage that has been achieved on the surface of RiVax with the 10 MAbs used in
this study. Interestingly, the anti-RTA VHHs fell into 11 different competition profiles, or
“bins,” which further resolves and refines the interrelationships among neutralizing and
nonneutralizing epitopes on the surface of RTA. Roughly half of the RTA-specific VHHs
had detectable toxin-neutralizing activity, although only three were classified as show-
ing strong activity, defined by a 50% inhibitory concentration (IC50) of less than 10 nM.
Localization of the binding sites of these VHHs by competition ELISA and X-ray
crystallography has revealed structural elements on RTA that likely constitute key
points of toxin vulnerability (40–42). TNA was associated with VHHs that contact (or are
proposed to contact) RTA’s -helix B and/or -helix D, defined by competition with
WECB2, and was also associated with those that contact (or are proposed to contact)
-helix F and the F-G loop, defined by competition with SyH7. Another somewhat
surprising finding from the companion study was the identification of a putative
supercluster of epitopes situated at the RTA-RTB interface and defined by competition
with SyH7. In other words, there was a population of toxin-neutralizing, RTB-specific
VHHs whose binding to ricin was inhibited by the RTA-specific MAb SyH7 and by the
VHH V5E1. Thus, the combination of competition ELISAs, HX-MS, and X-ray crystallog-
raphy using murine and camelid antibodies has resulted in a high-resolution B cell
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epitope map of RTA and RiVax that can now be exploited for the purpose of vaccine
and therapeutic development.
MATERIALS AND METHODS
Chemicals and reagents. Sodium chloride (crystalline; certified by the American Chemical Society
[ACS]), deuterium oxide, and guanidine hydrochloride were purchased from Fisher Scientific (Fair Lawn,
NJ). All other chemicals were obtained from Sigma-Aldrich, Inc. (St. Louis, MO), unless noted otherwise.
RiVax was expressed and purified as described previously (72), divided into aliquots, and stored at 80°C.
After they were thawed, RiVax samples were buffer exchanged into 10 mM sodium phosphate–150 mM
sodium chloride (pH 7.4). RiVax samples were over 98% pure as measured by sedimentation velocity-
analytical ultracentrifugation (SV-AUC) (data not shown). Proteolytic cleavage performed with an
N-terminal 6His affinity tag resulted in a nonnative N-terminal alanine in the amino acid sequence. This
alanine is assigned as residue zero in order to align the sequence numbering with the native RTA
sequence.
RTA-specific MAbs. The MAbs used in this study are shown in Table 1 and were purified by protein
A chromatography at the Dana Farber Cancer Institute (DFCI) Monoclonal Antibody Core Facility (Boston,
MA). Immunocompetition sandwich ELISAs (shown in Fig. S1 in the supplemental material) were done as
follows. Nunc Immuno MicroWell 96-well plates were coated overnight with capture anti-RTA MAbs (1
g/ml). The following day, the plates were blocked with 2% goat serum, washed, and then overlaid with
a mixture of biotin-tagged ricin and competitor MAb (10 g/ml). The amount of biotin-ricin used in the
competition ELISA was adjusted to the 90% effective concentration (EC90) for each capture MAb. After 1 h of
incubation, the plates were washed and developed with streptavidin-horseradish peroxidase (HRP) antibody
(Southern Biotech) (1:500) and TMB (3,3=,5,5=-tetramethylbenzidine). The percentage of inhibition of ricin
binding to the capture MAb in the present of a competitor MAb was calculated from the values correspond-
ing to the optical density at 450 nm (OD450) as follows: 1  OD450 value (biotin-ricin plus competitor
MAb)/OD450 value (biotin-ricin without competitor MAb)  100.
HX-MS. HX-MS experiments were conducted using a LEAP H/DX PAL system (Carrboro, NC) and a
model 6530 quadrupole time of flight (QTOF) mass spectrometer (Agilent, Santa Clara, CA). Three
microliters of RiVax prepared at 20 M was incubated with 27 l of deuterated buffer (10 mM sodium
phosphate, 150 mM sodium chloride, pD 7.4) at 25°C for 13 to 86,400 s. The final concentration of the
MAbs was 40 M and that of RiVax was 20 M, resulting in a 2-fold molar excess of antibody. Incubation
at each HX time was performed in triplicate. For experiments performed in the presence of MAb, RiVax
was prepared at 20 M with a MAb concentration of 40 M. Hydrogen exchange was quenched using
200 mM phosphate– 4 M guanidinium chloride (pH 2.5). Fifty-five microliters of the quenched sample was
then injected into a liquid chromatography (LC) system from online proteolysis performed using an
immobilized pepsin column (73) followed by desalting and chromatographic separation. The LC method
used included the use of an 18-min segmented gradient from 1% to 95% mobile phase B, with mobile
phase A consisting of 0.1% formic acid and mobile phase B of 90% acetonitrile– 0.1% formic acid. Tandem
MS (MS/MS) analysis was used to generate a peptide map of RiVax providing 100% sequence coverage
with 129 peptides (Toth et al., unpublished). The HX data were processed using HDExaminer software
(Sierra Analytics, Modesto, CA). Data were corrected for maximum deuteration as measured with a
deuteration control (RiVax was labeled in a pD 8 buffer for 18 h and then digested and analyzed as
described above). Backbone flexibility was quantified using the fraction of exchange after the shortest HX
time (13 s) as follows:




where Δm denotes measured mass increase (HX) and the infinity subscript designates the measured HX
for the deuteration control. For epitope mapping, HX data for each peptide from all HX times were
averaged into a single differential value representing free RTA minus MAb-bound RTA (ΔHX). A combi-
nation of significance testing and k-means clustering was applied and will be described elsewhere (Toth
et al., unpublished). In this work, epitopes were defined using only the most strongly protected category
from the k-means clustering.
Molecular graphics. All structures were displayed using PyMOL Molecular Graphics System Version
1.8 (PyMOL Molecular Graphics System; Schrodinger LLC, San Diego, CA), ricin holotoxin (PDB identifier
[ID]: 2AAI) (14), RTA (PDB ID: 1RTC) (74), or RiVax (PDB ID: 3SRP) (18). In mapping HX data to the
structures, residue conflicts from overlapping peptides were resolved as follows: intermediate protection
overwrote insignificant protection, and strong protection overwrote intermediate protection. In addition,
since the first two residues typically undergo rapid back-exchange during analysis (75), the first two
residues in each peptide were ignored during epitope mapping.
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